Comparison of PFS-OS between two treatment methods (surgery and then chemotherapy compared with neoadjuvant and then surgery) in patients with endometrial cancer: a retrospective study

Document Type : Original Article


1 Resident, Department of Obstetrics and Gynecology, Clinical Research Development Unit, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.

2 Assistant Professor, Department of Obstetrics and Gynecology, Endometriosis Research Center, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.

3 Associate Professor, Department of Obstetrics and Gynecology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.


Introduction: Endometrial cancer is one of the common diseases among women, which causes the death of many women in the world every year. The survival of patients and their response to treatment is determined based on clinical conditions and the stage of the disease. It has been determined that patients who are in the advanced stage (stage III and IV) have a shorter survival. The present study was conducted with aim to evaluate the survival of patients based on OS and PFS (overall survival and progression-free survival).
Methods In this retrospective cohort study, all patients with advanced endometrial cancer who were treated in Firouzgar and Rasoul Akram hospitals during the last 8 years from 2010 to 2018 were compared in two groups with different treatment methods (first neoadjuvant therapy and then surgery compared to first surgery and then adjuvant therapy). Data were analyzed by Stata software (version 14.1). The survival rate of patients was evaluated using the Kaplan-Meier approach. Factors affecting the survival rate were also analyzed using a Cox regression model. The investigation of factors affecting the response to treatment was also done in a multiple logistic regression model. P< 0.05 was considered statistically significant.
Results: There was no significant difference in terms of mean survival in patients who were treated with chemotherapy surgery and surgical chemotherapy (p>0.05). Total survival rate was higher in patients treated with standard method compared to patients who received chemotherapy first and then surgery.
Conclusion: There was no significant difference in the survival of patients in terms of treatment with chemotherapy surgery and surgical chemotherapy. However, the variable of surgery had the highest correlation in the recurrence of the disease and also the survival of the patients.


  1. Van Nyen T, Moiola CP, Colas E, Annibali D, Amant F. Modeling endometrial cancer: past, present, and future. International journal of molecular sciences 2018; 19(8):2348.
  2. Habu Y, Mitsuhashi A, Hanawa S, Usui H, Horikoshi T, Uno T, et al. High prevalence of pulmonary embolism prior to cancer therapies in patients with ovarian and endometrial cancers detected by contrast‐enhanced CT using D‐dimer as an index. Journal of Surgical Oncology 2021; 124(1):106-14.
  3. Raffone A, Travaglino A, Gabrielli O, Micheli M, Zuccalà V, Bitonti G, et al. Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer. Archives of gynecology and obstetrics 2021; 303(6):1393-400.
  4. Salarfard M, Yazdimoghaddam H, Abdollahi M, Karimi FZ. The effect of herbal medicines on vaginal atrophy in postmenopausal women: A systematic review and meta-analysis. Iran J Obstet Gynecol Infertil 2022; 24(13):100-18.
  5. McElroy JA, Hunter MI. Cadmium: a new risk factor for endometrial cancer?. Expert Review of Anticancer Therapy 2019; 19(5):355-8.
  6. Scaletta G, Dinoi G, Capozzi V, Cianci S, Pelligra S, Ergasti R, et al. Comparison of minimally invasive surgery with laparotomic approach in the treatment of high risk endometrial cancer: A systematic review. European Journal of Surgical Oncology 2020; 46(5):782-8.
  7. Sorosky JI. Endometrial cancer. Obstetrics & Gynecology 2012; 120(2 Part 1):383-97.
  8. De Lange NM, Ezendam NP, Kwon JS, Vandenput I, Mirchandani D, Amant F, et al. Neoadjuvant chemotherapy followed by surgery for advanced-stage endometrial cancer. Current Oncology 2019; 26(2):226-32.
  9. Miller DS, Filiaci VL, Mannel RS, Cohn DE, Matsumoto T, Tewari KS, et al. Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG Oncology/GOG0209). Journal of Clinical Oncology 2020; 38(33):3841-50.
  10. Marcos-Sanmartín J, Fernández JA, Sánchez-Payá J, Piñero-Sánchez ÓC, Román-Sánchez MJ, Quijada-Cazorla MA, et al. Does the type of surgical approach and the use of uterine manipulators influence the disease-free survival and recurrence rates in early-stage endometrial cancer?. International Journal of Gynecologic Cancer 2016; 26(9).
  11. Corrado G, Cutillo G, Pomati G, Mancini E, Sperduti I, Patrizi L, et al. Surgical and oncological outcome of robotic surgery compared to laparoscopic and abdominal surgery in the management of endometrial cancer. European Journal of Surgical Oncology (EJSO) 2015; 41(8):1074-81.
  12. Matsubara S, Mabuchi S, Takeda Y, Kawahara N, Kobayashi H. Prognostic value of pre-treatment systemic immune-inflammation index in patients with endometrial cancer. PloS one 2021; 16(5):e0248871.
  13. Chambers L, Jia X, Alhilli M. Impact of neoadjuvant chemotherapy on survival in women with endometrial cancer: A National Cancer Database analysis. American Society of Clinical Oncology; 2020.
  14. Engelsen IB, Akslen LA, Salvesen HB. Biologic markers in endometrial cancer treatment. Apmis 2009; 117(10):693-707.
  15. Secord AA, Havrilesky LJ, O'Malley DM, Bae-Jump V, Fleming ND, Broadwater G, et al. A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer. Gynecologic oncology 2009; 114(3):442-7.
  16. Papadia A, Bellati F, Ditto A, Bogani G, Gasparri ML, Di Donato V, et al. Surgical treatment of recurrent endometrial cancer: time for a paradigm shift. Annals of surgical oncology 2015; 22(13):4204-10.
  17. Hogberg T, Signorelli M, De Oliveira CF, Fossati R, Lissoni AA, Sorbe B, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer–results from two randomised studies. European journal of cancer 2010; 46(13):2422-31.
  18. Park HJ, Nam EJ, Kim S, Kim YB, Kim YT. The benefit of adjuvant chemotherapy combined with postoperative radiotherapy for endometrial cancer: a meta-analysis. European Journal of Obstetrics & Gynecology and Reproductive Biology 2013; 170(1):39-44.
  19. Makker V, Colombo N, Casado Herráez A, Santin AD, Colomba E, Miller DS, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. New England Journal of Medicine 2022; 386(5):437-48.
  20. Shalowitz DI, Epstein AJ, Buckingham L, Ko EM, Giuntoli II RL. Survival implications of time to surgical treatment of endometrial cancers. American Journal of Obstetrics and Gynecology 2017; 216(3):268-e1.
  21. Gottwald L, Pluta P, Piekarski J, Spych M, Hendzel K, Topczewska-Tylinska K, et al. Long-term survival of endometrioid endometrial cancer patients. Archives of Medical Science 2010; 6(6):937-44.
  22. Janda M, Gebski V, Davies LC, Forder P, Brand A, Hogg R, et al. Effect of total laparoscopic hysterectomy vs total abdominal hysterectomy on disease-free survival among women with stage I endometrial cancer: a randomized clinical trial. Jama 2017; 317(12):1224-33.